The tweet was deleted by the author.
But we saved everything 🙂.
Caribou Biosciences has presented new data on its allogeneic CAR-T cell programs, targeting lymphoma and multiple myeloma at the EHA congress.
The company continues to advance its pipelines, with the recent discussion during an interview with industry figures underscoring momentum in gene-edited immunotherapies for hematological malignancies.
Caribou Biosciences recently reported longer follow-up dose escalation data for CB-011 in relapsed or refractory multiple myeloma patients, highlighting progress in its cell therapy programs (CB-011 update). Earlier, the company participated in the Jefferies Global Healthcare Conference in New York, with a focus on cell therapy and CRISPR technologies (conference attendance). These developments reflect ongoing activity in Caribou's gene-edited therapeutic pipeline.